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Snakebite envenoming causes 138,000 deaths annually, and ~400,000 victims are left with 
permanent disabilities. Envenoming by saw-scaled vipers (Viperidae: Echis) leads to systemic 
hemorrhage and coagulopathy, and represents a major cause of snakebite mortality and 
morbidity in Africa and Asia. The only specific treatment for snakebite, antivenom, has poor 
specificity, low affordability, and must be administered in clinical settings due to its intravenous 
delivery and high rates of adverse reactions. This requirement results in major treatment delays 
in resource-poor regions and substantially impacts on patient outcomes after envenoming. Here 
we investigated the value of metal ion chelators as pre-hospital therapeutics for snakebite. 
Among the tested chelators, dimercaprol (British anti-Lewisite) and its derivative 2,3-
dimercapto-1-propanesulfonic acid (DMPS), were found to potently antagonize the activity of 
Zn2+-dependent snake venom metalloproteinases in vitro. Moreover, DMPS prolonged or 
conferred complete survival in murine preclinical models of envenoming against a variety of 
saw-scaled viper venoms. DMPS also considerably extended survival in a ‘challenge and treat’ 
model, where drug administration was delayed after venom injection, and the oral administration 
of this chelator provided partial protection against envenoming. Finally, the potential clinical 
scenario of early oral DMPS therapy combined with a delayed, intravenous dose of conventional 
antivenom provided prolonged protection against the lethal effects of envenoming in vivo. Our 
findings demonstrate that the safe and affordable repurposed metal chelator DMPS can 
effectively neutralize saw-scaled viper venoms in vitro and in vivo and highlights the promise of 






Snakebite envenoming is a neglected tropical disease (NTD) that affects ~5 million people 
worldwide each year, and leads to high mortality (~138,000/year) and morbidity (~400,000-
500,000/year), particularly in sub-Saharan Africa and southern Asia (1). In West Africa, the 
economic burden of snakebite has been estimated at 320,000 Disability Adjusted Life Years 
(DALYs) annually - a number higher than most other NTDs, including leishmaniasis, 
trypanosomiasis, and onchocerciasis (2). The highest burden of snakebite is suffered by the rural 
impoverished communities of low and middle income countries, who often rely on agricultural 
activities for their income (3). These activities put them at risk of snakebite by being exposed to 
environments inhabited by venomous snakes, and the remoteness of many of these communities 
makes accessing healthcare problematic (4). Consequently, it is estimated that 75% of snakebite 
fatalities occur outside of a hospital setting (5), as victims are often delayed in reaching a 
healthcare facility due to long travel times and/or suboptimal health-seeking behaviors. 
Crucially, treatment delays are known to result in poor patient outcomes, and often lead to life-
long disabilities, psychological sequelae, or death (6, 7). Further compounding this situation, 
species-specific antivenom, the only appropriate treatment for snakebite (1, 3), is often 
unavailable locally and, when present, is exceedingly expensive relative to the income of 
snakebite victims, despite being classified by the WHO as an essential medicine (8). 
Consequently, snakebite was classified as a ‘priority NTD’ by the World Health Organization 
(WHO) in 2017. Subsequently, the WHO has developed a strategy proposed to halve the number 
of snakebite deaths and disabilities by the year 2030, by improving existing treatments, 
developing new therapeutics, and empowering local communities to improve pre-hospital 
treatment (9). 
 
Snake venoms are mixtures of numerous toxin isoforms encoded by multiple gene families, 
whose composition varies both inter- and intra-specifically (10, 11). Venom variation makes the 
development of pan-specific snakebite treatments challenging due to the multitude of drug 
targets that need to be neutralized for any particular geographical region. Antivenoms consist of 
polyclonal antibodies (IgG or IgG-derived F(ab’)2 or Fab fragments) purified from the serum or 
plasma of animals hyperimmunized with snake venom(s). Venom toxin variation results in these 
products typically having limited or no efficacy against snake venoms not used in the 
manufacturing process (12). Furthermore, antivenoms have poor dose efficacy (only ~10-20% of 
antibodies are specific to venom toxins (13)), must be delivered intravenously, and have a high 
incidence of adverse reactions (as high as 75% of cases (14)), meaning that they must be 
delivered in a clinical setting (1). As advocated by the WHO (9), there is an urgent need for the 
development of rapid, effective, well-tolerated, and affordable interventions for treating tropical 
snakebite (9). Ideally, initial interventions would be safe for use outside of a clinical 
environment, thus facilitating rapid administration in a community setting and likely improving 
patient outcomes. 
The use of small molecule inhibitors to generically target key classes of snake venom toxins has 
recently attracted renewed interest as a potential therapeutic alternative to antivenom (15). 
Varespladib, a secretory phospholipase A2 (PLA2) inhibitor, has emerged as a promising drug 
candidate that protects against venom-induced lethality and limits the pathology associated with 
certain snakebites in preclinical animal models (16, 17). Varespladib was found to be particularly 
effective against PLA2-rich elapid venoms, but also showed some efficacy against a number of 
viper venoms (18). Molecules that counteract the activity of snake venom metalloproteinase 
(SVMPs) toxins have also been investigated in this regard. SVMPs are Zn2+-dependent, 
enzymatically active hemotoxins (19) involved in causing systemic hemorrhage and 
coagulopathy by actively degrading capillary basement membranes and/or interacting with key 
components of the blood clotting cascade (20). They are often the major toxin constituents of 
viper venoms (21). Peptidomimetic hydroxamate inhibitors that block the catalytic site of 
SVMPs (for example batimastat and marimastat) have been shown to abolish the local and 
systemic toxicity induced by saw-scaled viper (Echis ocellatus) venoms from Cameroon and 
Ghana (22), and dermonecrosis and hemorrhage caused by the venom of the Central American 
fer-de-lance (Bothrops asper) (23). Similarly, metal ion chelators (referred to as metal chelators 
hereafter) that deplete the Zn2+ pool required for SVMP function, including EDTA (23, 24), can 
prevent hemorrhage, myotoxicity, and/or lethality caused by E. ocellatus or E. carinatus venoms 
(25, 26). These previous studies suggest that small molecule inhibitors targeting SVMPs may 
represent good candidates for delaying or even neutralizing the toxicity caused by SVMP-rich 
venoms. However, neither marimastat nor batimastat are currently available as licensed 
medicines, whereas EDTA is not desirable for further development as a therapeutic due to its 
poor specificity for zinc and high affinity for calcium, its poor safety profile, as well as a 
requirement for slow intravenous administration, which makes it unsuitable for use as a pre-
hospital therapeutic (27). 
Saw-scaled vipers (Viperidae: Echis spp.) represent one of the most medically-important groups 
of venomous snakes, with a broad distribution through Africa north of the equator, the Middle 
East, and western parts of South Asia (Fig. 1). Among these, E. ocellatus (the West African saw-
scaled viper) is responsible for most snakebite deaths in sub-Saharan Africa (2), with a case 
fatality rate of 20% in the absence of antivenom treatment (28), whereas the Indian saw-scaled 
viper (E. carinatus) is one of the ‘big four’ snake species that together cause the vast majority of 
India’s 46,000 annual snakebite deaths (5). Envenomings by saw-scaled vipers cause local tissue 
damage and venom-induced consumption coagulopathy (VICC), the combination of which 
routinely results in life-threatening internal hemorrhage (29, 30). Crucially, the predominant 
toxins in saw-scaled viper venoms are typically SVMPs (27.4-75.7% of all venom proteins; Fig. 
1) (11, 24), and thus these snakes are tractable models for testing the development of new 
SVMP-specific small molecule-based snakebite therapeutics. Consequently, in this study we 
investigated the in vitro and in vivo neutralizing potential of repurposed licensed metal chelators 
against a variety of saw-scaled viper venoms (genus Echis). We demonstrate that 2,3-
dimercapto-1-propanesulfonic acid (DMPS), an existing licensed drug indicated for treating 
chronic and acute heavy metal poisoning, effectively neutralizes venom-induced lethality in vivo 




Metal chelators inhibit venom activity in vitro 
Saw-scaled viper venoms are highly enriched in SVMPs (45.4-72.5% of all toxins), with the 
exception of that of E. leucogaster, whose venom proteome is dominated by PLA2s (39.7%; 
SVMPs 27.4%) (Fig. 1). Because SVMP activity is Zn2+-dependent, we assayed the ability of 
three metal chelators to inhibit venom SVMPs from six saw-scaled vipers with a wide 
geographical distribution (Fig. 1), namely E. ocellatus (Nigeria), E. carinatus (U.A.E. and India), 
E. pyramidum (Kenya), E. leucogaster (Mali), and E. coloratus (Egypt). The three chosen 
chelators – dimercaprol (British anti-Lewisite), 2,3-dimercapto-1-propanesulfonic acid (DMPS, 
also known as unithiol), and dimercaptosuccinic acid (DMSA, also known as succimer) – share a 
common backbone (fig. S1) and are licensed medicines used to treat acute and chronic heavy 
metal poisoning (31). We also compared the efficacy of these chelators to that of EDTA, a metal 
chelator that we have previously shown to inhibit the SVMP activity and lethal effects of E. 
ocellatus venom (24). 
We used a kinetic fluorogenic assay to quantify venom SVMP activity and its neutralization by 
metal chelators. All six Echis venoms displayed similar amounts of SVMP activity (fig. S2A), 
with slightly higher activity observed for Indian E. carinatus. When testing the neutralization of 
this activity across a 1000-fold concentration range for the various metal chelators (150 µM to 
150 nM), dimercaprol was found to consistently be the most effective (IC50: 0.04-0.18 µM), 
followed by DMPS≈EDTA (IC50: 1.64-3.40 and 2.25-4.43 µM, respectively) and then DMSA 
(IC50=19.29-35.09 µM) (Fig. 2, Data file S1). However, all drugs inhibited >98% of venom 
activity at the maximal concentration tested (150 µM), with dimercaprol, DMPS, and EDTA 
displaying comparable potency at the 15 µM concentration, irrespective of the snake species 
tested. 
We next tested the inhibitory capacity of the chelators in a venom-induced plasma clotting assay, 
an in vitro model for in vivo coagulopathy (32). Because all tested Echis venoms are 
procoagulant (24, 33) and exhibit rapid clotting profiles (fig. S2B), we measured venom 
neutralization as a shift in these profiles towards that of the plasma-only control. Similar to the 
SVMP assay, dimercaprol outperformed DMPS and DMSA (IC50: 0.14-1.36, 1.18-27.65, and 
18.78-147 µM, respectively). However, all three drugs showed considerable neutralization (60.6-
100% inhibition) of the coagulopathic effects of each of the venoms at the maximal inhibitor 
dose tested (150 µM) (Fig. 3, Data file S1). 
Except for Indian E. carinatus venom (IC50 = 2.18 µM), EDTA did not extensively inhibit venom 
activity in the plasma assay due to its proclivity towards calcium, which is added to the citrated 
plasma in excess as a required cofactor to stimulate clotting. Because five of the six Echis 
venoms are capable of inducing clotting in a calcium-independent manner (24, 33), we repeated 
the assay in the absence of calcium and in this scenario, EDTA was effective at inhibiting 
venom-induced plasma clotting, presumably through effective chelation of Zn2+ in the absence of 
calcium (fig. S3, Data file S1). Despite this, EDTA was generally outperformed by both 
dimercaprol and DMPS under these conditions (IC50: 4.89-253.10 versus 0.49-13.98 and 2.18-
7.55 µM, respectively).  
Saw-scaled viper venoms contain SVMPs that potently activate prothrombin, and therefore 
contribute to VICC in envenomed patients (24). Given the success of metal chelators in 
neutralizing procoagulant venom activity in the above assays, we next tested whether they could 
prevent the cleavage of prothrombin. Recombinant human prothrombin was either preincubated 
with venom or venom and inhibitor (150 or 500 µM doses of each metal chelator), with 
prothrombin profiles subsequently examined by SDS-PAGE (fig. S4). All four chelators 
demonstrated protective effects against each saw-scaled viper venom, with the exception of E. 
coloratus, at the higher dose, although dimercaprol and EDTA outperformed DMPS and DMSA 
at the lower dose (150 µM) (fig. S4). 
 
Dimercaprol and DMPS protect against venom-induced lethality 
Given the in vitro efficacy of the tested chelators, which generally outperformed EDTA, a drug 
shown to neutralize the lethal effects of saw-scaled viper venoms in vivo (24), we next 
investigated whether these compounds could protect against venom-induced lethality in a 
conventional in vivo model of envenoming. To this end, we used a refined version of the WHO-
recommended standard protocol for the preclinical testing of antivenoms (ED50 assay). This 
assay requires the preincubation of venom and therapy before their intravenous co-administration 
to mice. Groups of male CD1 mice (n=5) were injected via the tail vein with 2.5 x lethal dose 50 
(LD50) of E. ocellatus venom (Nigeria, 45 µg) in the presence or absence of the various chelators 
(60 μg dose of dimercaprol, DMPS, or DMSA per mouse). We used E. ocellatus as our model 
because this species has been referred to as the most medically-important snake in West Africa 
(2). The positive control venom-only group all succumbed to the lethal effects of the venom 
within the first hour (3-50 min). However, the groups of mice that received dimercaprol or 
DMPS alongside a lethal dose of venom survived until the end of the experiment (6 h) (Fig. 4A-
B). DMSA was found to be less effective, as only three of the five experimental animals survived 
(Fig. 4C). The metal chelators were also well-tolerated when administered alone (Fig. 4, dotted 
lines), with no overt signs of toxicity.  
We have previously demonstrated that plasma thrombin-antithrombin (TAT) concentrations, a 
marker of thrombin generation, are a useful biomarker for assessing the efficacy of therapeutics 
against saw-scaled viper envenoming in experimental animals (24). In the current study, 
mortality correlated with high TAT concentrations (~1200 ng/ml, R2=0.866, fig. S5), whereas 
low TAT concentrations (Fig. 4D) were observed in mice where metal-chelators prevented 
lethality, and these concentrations were comparable to those in non-envenomed control animals 
(10.2-15.9 ng/ml). In line with our in vitro findings, dimercaprol caused the greatest decrease in 
TAT concentrations (~40-50 ng/ml), followed by DMPS (~170-252 ng/ml) and then DMSA 
(~300-666 ng/ml).  
  
Chelator efficacy varies among snake species 
We next tested the capability of the two metal chelators that provided complete protection 
against the lethal effects of E. ocellatus envenoming (dimercaprol and DMPS) at neutralizing 
venom from related saw-scaled viper species. We chose the next two most medically important 
Echis species (E. pyramidum from Kenya and E. carinatus from India), each of which has a 
relatively different venom composition when compared to that of E. ocellatus (Fig. 1, (11, 34)). 
Whereas both E. pyramidum and E. carinatus venoms remain dominated by SVMPs, they each 
have higher proportions of C-type lectin toxins (CTLs) (11.2% and 23.9%) and PLA2s (E. 
pyramidum, 21.5%) or disintegrins (E. carinatus, 14.0%) than E. ocellatus (CTL, 7.1%; PLA2, 
10.0%; disintegrins, 2.3%). Neither chelator was found to confer complete protection against 
both of these venoms when tested in vivo. Dimercaprol provided complete protection against 
lethality caused by E. carinatus, but was less effective against E. pyramidum (two deaths; 54 and 
165 min), whereas DMPS provided complete protection against E. pyramidum, but only partial 
neutralization against E. carinatus (two deaths; 89 and 110 min) (Fig. 5). TAT concentrations 
showed a consistent correlation with the survival data, with lethality corresponding to increased 
TAT concentrations (>322 ng/ml). We found it highly promising that both metal chelators were 
capable of preventing lethality in mice envenomed with two of the three venoms tested, and that 
for the third partial protection and significantly prolonged survival times were observed 
(P=0.0041 for E. carinatus venom-only vs. venom + DMPS; P=0.0037 for E. pyramidum 
venom-only vs. venom + dimercaprol) (Figs. 4 and 5).  
 
Delayed drug administration protects against lethality 
We initially designed our survival assays in line with the WHO-approved recommendations for 
the preclinical testing of antivenoms, whereby the preincubation of venom and treatment ensures 
optimal conditions for the neutralization of venom toxins. To modify this model to better mimic 
a real-life envenoming scenario, we next challenged groups of mice intraperitoneally with 90 µg 
(the equivalent of 5 x the intravenous LD50 dose) of E. ocellatus venom, followed by the 
administration of an intraperitoneal dose (120 μg) of dimercaprol or DMPS 15 minutes later. All 
experimental animals were then monitored for signs of envenoming for 24 h, along with those 
from the venom-only and drug-only control groups. None of the animals receiving metal 
chelators alone displayed any adverse effects over the 24 h period, whereas the venom-only 
group succumbed to the lethal effects of the venom within 1.5-4 h (Fig. 6A). Notably, the 
delayed dosing of DMPS protected against venom-induced lethality for over 12 h after initial 
envenoming, and two of the five experimental animals survived to the end of the experiment (24 
h) (Fig. 6A). The observed prolonged protection against envenoming provided by DMPS is 
promising, and it is worth noting that the death of the three mice between 12.6-24 h post-venom 
administration is likely due to the substantial clearance of DMPS in the absence of redosing, as 
previous research in rats and rabbits has shown that 85-89% of this chelator is excreted in the 
urine within 6 h after oral dosing (35, 36). Contrastingly, the delayed dosing of dimercaprol in E. 
ocellatus-envenomed mice offered considerably less protection than DMPS. Although two 
experimental animals also survived until the end of the experiment (24 h), three succumbed 
rapidly, and at times closely matching those of the venom-only control (111, 125, and 150 min 
vs. 110, 110, and 143 min, respectively). These findings demonstrate that DMPS outperforms 
dimercaprol by providing prolonged protection against the lethal effects of E. ocellatus snake 
envenoming in a preclinical model more reminiscent of a real-world envenoming scenario 
(treatment delivery after envenoming). 
We next investigated whether the delayed administration of DMPS was equally effective against 
the venoms of E. pyramidum and E. carinatus. In line with our previous findings, DMPS was 
more effective at protecting against the lethal effects of E. pyramidum venom than those of E. 
carinatus, despite using a higher venom challenge dose (112 vs. 95 µg, respectively) (Fig. 6B 
and C). Although three animals died within the first 6 h (at 99, 227, and 365 min) in the E. 
pyramidum group, two survived for the duration of the experiment (24 h) (Fig. 6B), whereas all 
mice treated with E. carinatus venom succumbed within the first 6.5 h of the experiment, and 
thus the chelator only provided a slight delay in lethality compared with the venom-only control 
(Fig. 6C). TAT concentrations again correlated with lethality, with higher concentrations (>400 
ng/ml) observed in animals not protected by DMPS, in contrast to those that survived for the 
duration of the experiment (average of ~200 ng/ml) (Fig. 6D and fig. S5). 
 
DMPS with subsequent antivenom administration prolongs survival 
The results described above demonstrate impressive protective capabilities for a single small 
molecule (DMPS), when considering that snake venoms consist of mixtures of numerous (50 to 
>200) constituents. To better support the use of DMPS as a pre-hospital snakebite therapy, we 
next sought to model a scenario in which metal chelators were administered as a rapid 
intervention soon after a snakebite, followed by later antivenom therapy when the patient has 
reached a healthcare facility. Thus, we compared our earlier findings where E. ocellatus venom 
(90 µg) was administered intraperitoneally followed by DMPS (120 μg) via the same route 15 
min later, with mice receiving the same venom and drug regimen, but with the intravenous 
administration (as per clinical use) of antivenom 1 h after venom injection (45 min after DMPS 
administration). For this, we used EchiTabG, an ovine antivenom generated against the venom of 
E. ocellatus and with known preclinical and clinical efficacy (13, 37). In addition, we used two 
control groups: one that received antivenom intravenously 1 h after venom injection but did not 
receive DMPS, and another that received antivenom intraperitoneally 15 min after the venom, as 
a direct comparator for the DMPS dose. A 1 h delay in antivenom administration in the absence 
of DMPS resulted in the early death of two mice (within the first 4.5 h), which correlated with 
high TAT concentrations (554 and 728 ng/ml) (Fig. 7A). The antivenom control that was 
administered intraperitoneally at 15 min, again in the absence of DMPS, resulted in one early 
death (at 142 min). Thus, delayed delivery of high doses of effective antivenom was unable to 
provide complete protection against envenoming by E. ocellatus. Notably, the early 
intraperitoneal administration of DMPS at 15 min after envenoming, followed by the intravenous 
delivery of antivenom at 1 h, protected against the lethal effects of E. ocellatus venom in all 
experimental animals until the end of the experiment (24 h), thereby extending the survival times 
of envenomed animals that received DMPS alone by >11 h (first death at 12.6 h) (Fig. 7B). This 
treatment regimen was also associated with low TAT concentrations (13.6-23.2 ng/ml), 
approaching those of the non-envenomed control mice (10.2-15.9 ng/ml; Fig. 7B). In 
combination, these findings demonstrate that: (i) DMPS outperforms antivenom therapy when 
administered by the same route after venom delivery, (ii) DMPS outperforms antivenom therapy 
when delivered earlier, even when the antivenom is delivered intravenously, and (iii) the 
combination of early DMPS treatment followed by later antivenom administration provides 
prolonged protection against E. ocellatus venom-induced lethality. 
 
Oral DMPS followed by antivenom protects against venom lethality 
DMPS is formulated both as a solution for injection and as an oral capsule, with the latter 
making it particularly promising as an early intervention for administration outside of a hospital 
setting. Next, we investigated the preclinical efficacy of DMPS when dosed via the oral route. 
DMPS was dissolved into a solution containing molasses, which was then provided to 
experimental animals ad libitum via a pipette tip 1 min after venom injection (90 µg E. ocellatus 
venom administered intraperitoneally; 600 μg DMPS orally; n=5). We compared survival 
outcomes in experimental groups consisting of: (i) venom and molasses (sham) only, (ii) venom 
and oral DMPS only, (iii) venom, oral DMPS, and then antivenom delivered intravenously 1 h 
later, and (iv) venom, sham, and the later dose of antivenom (Fig. 7C). The DMPS dose was 
increased fivefold in these studies (600 μg vs. 120 µg) due to the anticipated lower 
bioavailability of the oral route compared with the intraperitoneal delivery described earlier. 
Nonetheless, this dose remained considerably lower than the maximal human equivalent dose 
permitted over 24 hr (2.44 mg/kg vs. 34.28 mg/kg) or even at a single dosing point (2.44 mg/kg 
vs 2.86 mg/kg), and the drug itself did not display any signs of toxicity in mice, as evidenced by 
survival data (Fig. 7C) and behavioral and post-mortem observations. Oral DMPS treatment 
resulted in comparable survival (2 of 5 experimental animals) to intraperitoneally delivered 
DMPS at the end of the experiment (24 h), although survival times were noticeably prolonged 
when the drug was delivered via the intraperitoneal route (Figs. 7B and 7C). These findings 
suggest that, as perhaps anticipated, the uptake and distribution of DMPS via oral administration 
are indeed inferior to the intraperitoneal route. In the comparator group, where envenomed mice 
received sham and antivenom only, only three mice survived to the end of the experiment, with 
two animals succumbing to the lethal effects of the venom (Fig. 7C). Critically though, the 
combination of oral DMPS followed by later antivenom administration resulted in the complete 
survival of experimental animals at 24 h (Fig. 7C), and those animals displayed TAT 
concentrations highly comparable to those observed in non-envenomed controls (average of 17.3 
ng/ml vs. 13.05 ng/ml in the control). These findings demonstrate that the early oral delivery of 
DMPS is capable of prolonging the survival of envenomed animals, and when combined with a 
later dose of antivenom, can provide prolonged and complete protection against snakebite 
lethality in vivo. 
 
DMPS effectively neutralizes venom-induced local hemorrhage and restores red blood cell 
(RBC) morphology 
The findings presented above demonstrate that DMPS protects against lethality and prevents the 
onset of severe coagulopathy in a variety of preclinical models. Next, we wished to explore the 
effectiveness of this chelator in preventing other pathological signs caused by saw-scaled viper 
venoms, specifically venom-induced hemorrhage and toxicity towards RBCs. To investigate the 
ability of DMPS to neutralize local hemorrhage, we injected groups of three male CD-1 mice 
intradermally with one minimum hemorrhagic dose (1 MHD [10 µg] (38)) of E. ocellatus 
venom. We then compared the size of the hemorrhagic lesions formed in the group receiving 
venom only with those in mice receiving the same dose of venom preincubated with 13.3 µg 
DMPS (1:1.33 venom to drug ratio, consistent with the lethality experiments). Whereas the 
venom-only group developed large, distinct, hemorrhagic lesions at 2 h after injection (average 
size of 41.24 mm2), those receiving the drug exhibited a substantial reduction (p=0.0007) in 
lesion size (average size of 1.43 mm2), nearly matching the complete absence of lesions observed 
in the PBS-only control group (Fig. 8).  
We next examined RBC morphology in blood films collected from our earlier intravenous 
experiments in which mice received E. ocellatus, E. carinatus, or E. pyramidum venom or those 
venoms preincubated with DMPS. Envenomation correlated with marked echinocytosis (the 
presence of crenated or ‘burr’ cells) across the three venoms tested, but the intravenous 
administration of DMPS fully rescued normal RBC morphology in mice treated with E. ocellatus 
venom (fig. S6). In addition, some protection was also observed against the venoms of E. 
pyramidum and E. carinatus, and the resulting cell morphology closely matched that observed in 
control blood samples, although limited intravascular hemolysis marked by ‘ghost cells’ was 
noted in these cases (fig. S6). When assessing the RBC morphology in blood films sourced from 
E. ocellatus envenomed mice in which drug administration was delayed, similar findings were 
observed. The intraperitoneal administration of E. ocellatus venom also resulted in the formation 
of echinocytes due to the expansion of the outer leaflet of the RBC membrane (fig. S7). 
Echinocytosis observed following rattlesnake (Crotalus spp.) envenoming was previously 
associated with the action of PLA2 toxins (39). However, we suspect that SVMPs may be 
responsible in the case of saw-scaled vipers, as DMPS was unable to inhibit the PLA2 or serine 
protease activities of fractionated E. ocellatus venom (fig. S8), yet the oral administration of 
DMPS markedly reduced the number of echinocytes present in the blood films (fig. S7). The 
delivery of antivenom alone at 1 h after venom delivery also generally rescued this RBC 
phenotype, though a small number of echinocytes and ghost cells remained present (fig. S7). The 
combined administration of both DMPS and antivenom resulted in a further reduction in the 
number of abnormal cells (fig. S7). In combination, these findings demonstrate that the treatment 
of experimentally envenomed animals with DMPS protects them from venom-induced local 




Here, we demonstrate that metal chelators can likely be repurposed as effective snakebite 
therapeutics, particularly when directed against snake venoms rich in metalloproteinases. 
Chelators have demonstrated safety profiles, are licensed medicines, and show considerable 
promise as affordable treatments for snakebite in low/middle-income countries (~8-12 USD/100 
mg oral capsule versus 48-315 USD per vial of antivenom (8), with 5-10 vials often required per 
envenoming). Moreover, the doses at which these SVMP inhibitors show efficacy are >100-fold 
lower than current immunoglobulin-based treatments (60 µg of drug versus 7.5 mg of antivenom 
for intravenous administration used in this study). The combination of these characteristics 
makes them highly amenable for investigation for clinical use in a pre-hospital setting, thus 
potentially dramatically reducing the long time to treatment typically observed after snakebite, 
which has a known major detrimental impact on patient outcomes (40, 41).  
Among the metal chelators explored in this study, DMPS, a hydrophilic heavy-metal chelator, 
was effective in preventing lethality in vivo in an intravenous model of snakebite envenoming, as 
well as in prolonging survival in mouse models where the venom challenge was followed by a 
delayed administration of the drug. Our challenge and treatment model attempted to replicate a 
clinical situation in which a victim would be bitten, would subsequently receive the metal 
chelator soon after, and would be later admitted to a healthcare facility where they would be 
treated with antivenom (if required). In both of our models (venom intraperitoneally/DMPS 
intraperitoneally or venom intraperitoneally/DMPS orally), the delayed administration of DMPS 
resulted in prolonged animal survival of ~17 h and ~10 h compared to the venom-only controls 
for the intraperitoneal and oral dosing, respectively. Moreover, when DMPS administration was 
followed by an intravenous dose of antivenom 1 h later, complete survival at 24 h after 
envenoming was observed in all cases, irrespective of whether the drug was delivered 
intraperitoneally or orally. These findings demonstrate that rapid DMPS intervention can 
substantially delay the onset of venom lethality, whereas antivenom administration alone (either 
intraperitoneally as a drug-matched control or intravenously with a 1 h delay) was insufficient to 
fully neutralize venom activity. In addition to providing protection against lethality, we found 
that DMPS restored parameters indicative of normal coagulation,  protected against damage to 
RBCs in both the preincubation and delayed administration models, and effectively prevented 
the formation of localized hemorrhagic lesions in a morbidity model of snakebite envenoming. 
These results highlight not only the promise of DMPS as a systemic intervention against 
envenoming, but also as a potential candidate drug for preventing local tissue damage after 
snakebite.   
DMPS is approved in Germany for treating mercury intoxication (marketed as Dimaval) and is 
available as both a 100-mg capsule for oral dosing and a 250-mg ampoule for intravenous or 
intramuscular administration. In humans, DMPS is readily absorbed after oral administration, 
can be detected in the plasma 30-45 min after administration, and reaches peak plasma 
concentrations 3-4 h after ingestion (42), making it a strong candidate as an early, pre-hospital, 
therapeutic intervention. Moreover, the drug forms complexes with plasma proteins via disulfide 
linkages, which results in slow release and prolongation of its clinical half-life to ~20 h, thus 
extending its efficacy window (43). DMPS also appears to exhibit high specificity for zinc, as 
previous preclinical research performed in rabbits and dogs showed no significant changes in the 
concentrations of iron or calcium, despite the intravenous or oral administration of the drug for 
prolonged periods (50-315/mg/kg/week for 10-26 weeks (44, 45). Importantly, no major side 
effects or teratogenic effects have been reported (46, 47), even with repeated oral administration 
spanning months in animals (126 mg/kg/day in rats for 5 days/week for 66 weeks (46); 45 
mg/kg/day over 6 months in beagles (45)) or several days in humans (~15 g DMPS given as a 
mixed regimen parenterally and orally over 12 days (48)). In our study, we used a single 
therapeutic dose that scales up to 1/14th of the maximal daily oral human equivalent dose 
regimen for acute heavy metal intoxication (2.44 mg/kg vs. 34.28 mg/kg). However, even under 
these sub-maximal and single dose conditions, DMPS prolonged survival for at least 12 h in 
mice envenomed with E. ocellatus venom, suggesting that the drug can effectively counteract 
systemic venom toxicity within a defined therapeutic window. Its efficacy in the intraperitoneal 
model superseded that of oral administration, likely due to increased bioavailability and 
distribution, whereas its decrease in efficacy over time (>12 h) seems likely to be linked to its 
excretion in the urine. Previous studies in rats and rabbits indicate that >85% of the drug is 
eliminated during the first 6 h (35, 36), as opposed to the ~20 h half-life observed in humans. 
Considering that in our model the drug was only administered once, we hypothesize that 
repeated dosing may continue to effectively neutralize venom SVMPs, thus expanding the 
protective interval. This should be explored in future studies.  
Of the remaining metal chelators tested in this study, dimercaprol showed some early promise as 
a snakebite therapeutic. Dimercaprol chelates a variety of heavy metals, including lead, arsenic, 
gold, and mercury, and provided the most effective venom inhibition in vitro. This chelator also 
neutralized the lethal effects of E. ocellatus and E. carinatus venoms in vivo in the coincubation 
model, although it had no efficacy in the more clinically-relevant ‘challenge and treat’ preclinical 
model. In addition, dimercaprol comes with several challenges for clinical use (49), including its 
formulation in peanut oil, requirement for administration via a deep, painful intramuscular 
injection, a number of reported adverse reactions, and a small safety margin (50). Given these 
considerations, its more hydrophilic derivatives offer safer alternatives. Consequently, both 
DMSA and DMPS have been advocated as the drugs of choice for the contemporary treatment of 
heavy metal poisoning (27). Our results here, however, demonstrate that DMSA shows a lack of 
preclinical efficacy against the medically important snake venoms investigated, thus strongly 
justifying the selection of DMPS as our lead chelator for future clinical translation. 
The WHO-recommended protocol for testing snakebite therapies recommends the preincubation 
of venom with antivenom, which artificially promotes the binding of venom toxins with the 
therapy. Although this is a necessary first step in assessing the therapeutic potential of a 
treatment by providing a ‘best-case’ scenario, this method does not accurately reflect snakebite, 
where venom is delivered before treatment. To overcome this, we used an intraperitoneal 
challenge/treatment model whereby the treatment was administered after venom, mirroring a 
more realistic scenario. However, no in vivo mouse model, regardless of venom or drug dosage, 
route of administration, or time between venom injection and drug treatment, can ever fully 
reflect a human snakebite. This is because the venom dose in mice is usually high (45-112 µg) to 
induce rapid lethality (<4 h) and avoid prolonged suffering in experimental animals. In contrast, 
lethality from saw-scaled viper bites in humans does not typically occur in <12 h (29). Thus, the 
onset of pathology is much faster in the animal model, and drug uptake and pharmacokinetics 
will likely differ due to different circulatory volumes. Nevertheless, the current model is still 
highly useful in evaluating antivenom efficacy and is the best preclinical model available for 
assessing potential therapeutic interventions for snakebite. Furthermore, snake venoms are toxin 
cocktails (10), and their toxin composition can vary extensively among species (11). It is worth 
noting that DMPS displayed superior efficacy against the venoms of E. ocellatus and E. 
pyramidum, compared with the venom of the related species E. carinatus, when used as a solo 
therapy. Nevertheless, DMPS did offer some protection against E. carinatus venom and 
prolonged survival in experimental animals. These differences in efficacy likely reflect variation 
in the toxin constituents found in the venom of these species (Fig. 1, (11, 34)), because a similar 
lack of preclinical efficacy has been observed when using antivenom made against E. ocellatus 
to neutralize E. carinatus venom (13) and, conversely, the clinical use of E. carinatus antivenom 
for treating bites by E. ocellatus has resulted in poor patient outcomes (51, 52). Despite these 
limitations, we suggest that DMPS may be a useful early intervention therapeutic to delay the 
onset of snakebite pathology caused by a variety of SVMP-rich venoms, particularly when 
subsequently coupled with species-specific antivenom. Future work should explore the breadth 
of DMPS efficacy in combination with antivenom, specifically to assess whether this 
combination therapy approach may reduce the number of costly vials of antivenom that are 
currently required to effect cure after snakebite. 
Lastly, although we have shown here that DMPS is effective in counteracting the activity of 
SVMP toxins, it cannot neutralize other toxin classes, such as the enzymatically active serine 
proteases and PLA2s also found in E. ocellatus venom. Thus, although oral DMPS may prove to 
be an effective early intervention for delaying the onset of pathology caused by many viperid 
snakes, which typically have a high abundance of SVMPs in their venom (21), snakebite victims 
may still require immediate transport to a healthcare facility in case antivenom therapy is 
required to neutralize other pathogenic, or even potentially lethal, toxin constituents. Future 
treatments consisting of mixtures of small molecules, each targeting different toxin types, could 
prove particularly valuable as more generic drugs against viper venoms, particularly since such 
inhibitors with specificities towards different toxin types have recently been described (15, 53). 
In addition, the further combination of small molecule inhibitors with conventional or next-
generation recombinant human/humanized oligoclonal antivenoms (54) may represent a 
particularly promising treatment strategy, particularly because this is an actively developing field 
aimed at generating safer and more effective snakebite therapeutics. 
Despite these described limitations, DMPS remains a strong candidate for translation for clinical 
use in snakebite envenoming. Given its high tolerability and availability of an oral formulation, 
DMPS is highly suitable for repurposing for treating snakebite, particularly against bites by the 
West African saw-scaled viper E. ocellatus, when considering the preclinical efficacy observed 
here. This species is an ideal choice for testing the clinical utility of DMPS, because it is 
responsible for thousands of deaths in Africa every year (2). We envision the implementation of 
a Phase 2 clinical trial in which snakebite victims would be given DMPS as an immediate pre-
hospital intervention followed later by antivenom upon arrival at a healthcare facility, compared 
with a second arm of the trial receiving conventional antivenom therapy only. However, first it 
will be important to undertake a Phase 1 trial to identify an optimal dosing regimen for DMPS 
within an African population, which is necessary because snakebite is an acute event, and thus 
the optimal bioavailability is likely to differ from that of the current clinical indication of heavy 
metal poisoning, where frequent dosing can be repeated for several weeks. Collectively, our data 
demonstrate that repurposing of inexpensive metal chelators can protect against the lethal effects 
of envenoming by snakes with SVMP-rich venoms. Although antivenom may be required 
secondarily, DMPS seems likely to delay the onset of severe envenoming by these snakes and 
may facilitate a reduction in the dose of costly and poorly tolerated antivenom. Ultimately these 
findings advocate for further research into the utility of small molecule inhibitors for rapidly and 
generically treating the world’s most lethal neglected tropical disease. 
Materials and Methods 
 
Study design 
The study used a variety of in vitro and in vivo assays to determine the efficacy of metal 
chelators against snakebite. For all in vitro kinetic experiments testing the dose-efficacy of 
chelators, the assays were performed in at least triplicate and each experimental repeat consisted 
of technical duplicates or triplicates. For the animal lethality studies, experiments were 
performed on groups of five male CD-1 mice (18-20 g). We first followed a modified version of 
the established WHO protocol (55) for testing intravenous treatment efficacy in a preincubation 
model of envenoming. Subsequently, we developed an intraperitoneal delivery-based ‘challenge 
and treat’ model of envenoming to explore venom neutralisation with delayed drug 
administration. For the hemorrhagic lesion studies, venom and/or drug was delivered 
intradermally into groups of three male CD-1 mice (18-20 g). For all animal experiments, mice 
were randomly distributed across groups, and the experimenters assessing the outcomes were 
blinded to the intervention. Mouse blood samples were collected from experimental animals via 
cardiac puncture after euthanasia by rising concentrations of CO2. Resulting plasma samples 
were assessed for markers of coagulopathy in duplicate using commercial ELISA kits, with 3 to 
5 mice being sampled. The numbers for all biological repeats are given in the respective figure 
legends. Detailed descriptions of all of the Materials and Methods used in this study are provided 
in the Supplementary Materials.  
 
In vivo studies 
All animal experiments were conducted using protocols approved by the Animal Welfare and 
Ethical Review Boards of the Liverpool School of Tropical Medicine and the University of 
Liverpool, and performed in specific pathogen-free conditions under licensed approval of the UK 
Home Office and in accordance with the Animal [Scientific Procedures] Act 1986 and 
institutional guidance on animal care. All animals were housed in groups of 5 with water and 
food ad libitum. Experimental design was based upon refined WHO-recommended protocols (8, 
55), with the observers being blinded to the experimental groups. The median lethal dose (venom 
LD50) for E. ocellatus (Nigeria), E. carinatus (India) and E. pyramidum (Kenya) venoms (18, 19, 
and 16 µg per 20 g mouse, respectively) were previously determined (8, 24, 55). Drug stocks 
were freshly prepared as follows: DMPS (1 mg/ml in PBS), DMSA (2 mg/ml in ethanol; final 
ethanol concentration of 15%), and Dimercaprol (1 mg/ml in water).  
 
Coincubation model of preclinical efficacy 
For our initial experiments, we used 2.5 x the intravenous LD50 doses of E. ocellatus (45 µg), E. 
carinatus (India) (47.5 µg), and E. pyramidum venoms (40 µg) in a refined version of the WHO 
recommended (55) antivenom ED50 neutralization experiments (24). Groups of five male 18-22 g 
CD-1 mice (Charles River) received experimental doses that consisted of either (a) venom only 
(2.5 x LD50 dose); (b) venom and drug (60 µg); or (c) drug only (60 µg). All experimental doses 
were prepared to a volume of 200 µl in PBS and incubated at 37 °C for 30 min before 
intravenous injection via the tail vein. Animals were monitored for 6 h and euthanized upon 
observation of humane endpoints (seizure, pulmonary distress, paralysis, hemorrhage). Deaths, 
times of death, and survivors were recorded, where “deaths/times of death” actually represent the 
implementation of euthanasia via rising concentrations of CO2 based on the defined humane 
endpoints. 
 
Challenge and treatment model of preclinical efficacy  
Next, we performed experiments where mice were initially challenged with venom, followed by 
delayed administration of the drug or antivenom. For these studies, we used an intraperitoneal 
model of venom administration to provide an acceptable time window to measure venom 
neutralization. Consequently, the venom challenge doses were increased to 5 x the intravenous 
LD50s (E. ocellatus [90 µg] and E. carinatus India [95 µg]) or 7 x the intravenous LD50s (E. 
pyramidum leakeyi [112 µg]) to ensure that complete lethality in the venom-only control group 
occurred within 4-5 h. Groups of five male 18-22 g CD-1 mice (Charles River) were injected 
with venom (100 µl final volume), followed by a drug dose that was scaled up in line with the 
increases in venom challenge doses (120 µg + PBS up to 200 µl) after 15 min. The experimental 
groups included mice receiving: (a) venom only (5 x intravenous LD50 or 7 x intravenous LD50) 
+ 200 µl PBS (15 min later); (b) venom (5 x intravenous LD50 or 7 x intravenous LD50) + drug 
(120 µg, 15 min later); and (c) sham (100 µl PBS) + drug (120 µg, 15 min later). 
 
For later ‘challenge and treat’ experiments with E. ocellatus venom only, we also explored the 
efficacy of antivenom, both with and without drug treatment. The antivenom used was 
EchiTAbG (MicroPharm Limited, batch EOG001330), an ovine monospecific anti-E. ocellatus 
antivenom validated for preclinical and clinical efficacy against envenoming by this species (13, 
37). The median effective dose (ED50) of EchiTAbG (Micropharm) against 5 x LD50 E. ocellatus 
(intravenous LD50 of 12.43 µg/mouse) venom was previously determined to be 58.46 µl (13). 
Consequently, we scaled up the antivenom dose to a dose that would protect all envenomed 
animals (2 x ED50; 168 µl), taking into account the slight difference in LD50 of our current E. 
ocellatus venom batch (17.85 µg/mouse vs. 12.43 µg/mouse). Antivenom was administered 
either intravenously 1 h after venom injection or intraperitoneally as a drug-matched control after 
15 min. The experimental design followed that described above with the following experimental 
groups: (a) E. ocellatus venom (90 µg; 5 x intravenous LD50) + drug (120 µg, 15 min later) + 
antivenom (intravenously 1 h later, 168 µl); (b) E. ocellatus venom (90 µg; 5 x LD50) + 
antivenom (intravenously, 1 h later, 168 µl); (c) E. ocellatus venom (5 x intravenous LD50) + 
antivenom (intraperitoneally 15 min later, 168 µl). For both sets of experiments described above, 
experimental animals were monitored for 24 h and euthanized upon observation of humane 
endpoints as described above. Unpaired two-tailed t-tests in GraphPad Prism 8.1 (GraphPad 
Software) were used to compare the survival times between groups treated with venom alone and 
venom + drug for E. carinatus and E. pyramidum venoms. 
 
 
Challenge and treatment model using oral DMPS  
We assessed the utility of DMPS as an oral therapeutic, using a similar ‘challenge and treat’ 
approach. We injected groups of mice intraperitoneally with 5 x intravenous LD50s of E. ocellatus 
venom, followed immediately (~1 min) by an oral dose of DMPS (600 µg, a dose lower than the 
human equivalent dose (56) [2.44 mg/kg vs. 34.28 mg/kg  maximal daily dose permitted, or 2.44 
mg/kg vs 2.86 mg/kg every 2 h]). The drug was dissolved in 50 µl of ~50 mg/ml molasses and 
administered orally (ad libitum) via a pipette tip to groups of 5 male CD-1 mice. The 
experimental groups included: (a) venom (90 µg) + molasses; (b) venom (90 µg) + oral DMPS 
(600 µg); (c) venom (90 µg) + oral DMPS (600 µg) + antivenom (intravenously, 1 h later, 168 
µl); (d) venom (90 µg) + molasses + antivenom (intravenously, 1 h later, 168 µl). Animals were 
monitored for 24 h and euthanized upon observation of humane endpoints, as described above. 
 
Neutralization of local hemorrhage by DMPS 
To assess the efficacy of DMPS against the local hemorrhagic effects of E. ocellatus venom, we 
used a variation of the minimum hemorrhagic dose (MHD) model (55). We used the previously 
determined MHD dose of E. ocellatus venom (10 µg, (38)) to induce hemorrhagic lesions via 
intradermal injection (50 µl) into the shaved dorsal skin of briefly anesthetized (isoflurane) male 
18-22g CD-1 mice (n=3, Charles River). To assess the ability of DMPS to neutralize 
hemorrhage, the following experimental groups were used: (a) E. ocellatus venom only (10 µg); 
(b) DMPS only (13.3 µg); (c) E. ocellatus venom (10 µg) preincubated with DMPS (13.3 µg) 
(1:1.33 ratio matched to the lethality experiments described earlier); (d) PBS control. All 
samples were preincubated at 37 ºC for 30 min before injection. Following previous 
recommendations (38), we implemented a humane reduction in the experimental time frame of 
this assay from 24 h to 2 h, because in the venom-only control group, venom injection resulted in 
a clearly measurable hemorrhagic lesion of ~8 mm in diameter after 2 h. The animals were 
continuously monitored for 2 h, after which they were euthanized via rising concentrations of 
CO2. Resulting hemorrhagic lesions were excised, measured in two directions using electronic 
calipers, and digitally photographed alongside color standards (57). 
 
Statistical analysis 
The areas under the curve for kinetic data (n=3) and the maximum clotting velocity data were 
plotted with SEMs. Unpaired two-tailed t-tests were performed in GraphPad Prism 8.1 
(GraphPad Software) and used to statistically compare the survival times between groups treated 
with venom alone and venom + drug for both E. carinatus and E. pyramidum, and to estimate the 
significance of the reduction in lesion size observed in the MHD model. For all ELISA 
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Fig. 1. The geographical distribution and venom toxin composition of saw-scaled vipers 
(genus Echis). 
Map of saw-scaled viper distribution with the locales of the studied species indicated by 
red stars. Echis distribution areas and corresponding venom proteomes are highlighted by the 
following colors: light orange (E. leucogaster), blue (E. ocellatus), green (E. carinatus), pink (E. 
pyramidum), violet (E. coloratus). Toxin proteome abundances were taken from (11, 58) and 
generated in this study for E. leucogaster. Toxin family key: SVMP, snake venom 
metalloproteinase; SVSP, snake venom serine proteinase; PLA2, phospholipase A2; CTL, C-type 
lectins; LAAO, L-amino acid oxidase; SVMPi, SVMP inhibitors; DIS, disintegrin; CRISP, 
cysteine-rich secretory protein. 
 
Fig. 2. Metal chelators inhibit SVMP toxin activity of saw-scaled viper venoms. 
The neutralizing capability of four metal chelators against the SVMP activity of six Echis 
venoms. Data are presented for four drug concentrations, from 150 µM to 150 nM (highest to 
lowest dose), expressed as percentages of the venom-only sample (100%, dotted red line). The 
negative control is presented as an interval (dotted black lines) and represents the values 
recorded in the PBS-only samples (expressed as % of venom activity), where the highest and the 
lowest values for each set of experiments are depicted. Inhibitors are color-coded (dimercaprol, 
red; DMPS, blue; DMSA, purple; EDTA, dark blue). The data represent triplicate independent 
repeats with SEMs, where each repeat represents the average of n≥2 technical replicates. 
 
Fig. 3. Metal chelators inhibit the procoagulant activity of saw-scaled viper venoms.  
The neutralizing capability of four metal chelators against the procoagulant activity of six Echis 
venoms. Data are presented for four drug concentrations, from 150 µM to 150 nM (highest to 
lowest dose), expressed as the maximum clotting velocity (middle dotted red line and 
surrounding interval indicates the maximum clotting velocity of the venom and represents the 
average ± SEM). The negative control is presented as an interval (dotted black lines, including 
the average and average ± SEM; this may appear as a single black line if the interval is very 
narrow and lines overlap) and represents normal plasma clotting. Inhibitors are color-coded 
(dimercaprol, red; DMPS, blue; DMSA, purple; EDTA, dark blue). The data represent triplicate 
independent repeats with SEMs, where each repeat represents the average of n≥2 technical 
replicates. 
 
Fig. 4. Metal chelators prevent or delay lethality in vivo when preincubated with Echis 
ocellatus venom. 
Kaplan-Meier survival graphs for experimental animals (n=5) receiving venom preincubated (30 
min at 37 C) with different metal chelators via the intravenous route. Survival of mice receiving 
45 µg of E. ocellatus venom (2.5 × LD50 dose) with and without 60 µg of dimercaprol (A), 60 µg 
of DMPS (B), or 60 µg of DMSA (C). Drug-only controls are presented as black dotted lines at 
the top of each graph, and the end of the experiment was at 6 h. None of the drugs exhibited 
toxicity at the given doses. (D) Quantification of TAT concentrations in envenomed animals. 
Where the time of death was the same within experimental groups (early deaths or complete 
survival), TAT concentrations were quantified for n=3, and where times of death varied, n=5. 
The data are displayed as means of the duplicate technical repeats plus SDs. 
 
Fig. 5. The efficacy of metal chelators against other medically important Echis venoms. 
Kaplan-Meier survival graphs for experimental animals (n=5) receiving Echis pyramidum or E. 
carinatus (India) venom preincubated (30 min at 37 C) with different metal chelators via the 
intravenous route. Survival of mice receiving 40 µg of E. pyramidum venom (A), and 47.5 µg of 
E. carinatus (India) venom (both represent the 2.5 × LD50 dose) (B) with or without 60 µg of 
dimercaprol or DMPS. Drug-only controls are presented as black dotted lines at the top of each 
graph. None of the drugs exhibited toxicity at the given doses. The end of the experiment was at 
6 h after injection. Quantification of TAT concentrations in envenomed animals is displayed in 
the right panels. Where the time of death was the same within experimental groups (early deaths 
or complete survival), TAT concentrations were quantified for n=3, and where times of death 
varied, n=5. The data are displayed as means of the duplicate technical repeats plus SDs. 
 
Fig. 6. DMPS delays lethality in vivo in a ‘challenge and treat’ model of envenoming. 
Kaplan-Meier survival graphs for experimental animals (n=5) receiving venom (intraperitoneal 
administration), followed by delayed drug treatment (intraperitoneally 15 min later). (A) 
Survival of mice receiving 5 x the intravenous LD50 dose of E. ocellatus venom (90 µg) with or 
without 120 µg of drug (dimercaprol or DMPS) 15 min later. (B) Survival of mice receiving 7 x 
intravenous LD50 dose of E. pyramidum venom (112 µg) with or without 120 µg of DMPS 15 
min later. (C) Survival of mice receiving 5 x intravenous LD50 dose of E. carinatus (India) 
venom (95 µg) with or without 120 µg of DMPS 15 min later. For (A), (B), and (C), drug-only 
controls are presented as black dotted lines at the top of each graph (none of the drugs exhibited 
toxicity at the given doses), and the end of the experiment was at 24 h. (D) Quantification of 
TAT concentrations in envenomed animals. Where the time of death was the same within 
experimental groups (early deaths or complete survival), TAT concentrations were quantified for 
n=3, and where times of death varied, n=5. The data are displayed as means of the duplicate 
technical repeats plus SDs. EOC, E. ocellatus; EPL, E. pyramidum; ECAR, E. carinatus. 
 
Fig. 7. Oral DMPS followed by later administration of antivenom protects against in vivo 
lethality caused by Echis ocellatus venom. 
Kaplan-Meier survival graphs for experimental animals (n=5) receiving E. ocellatus venom (90 
µg, 5 × intravenous LD50 dose, via intraperitoneal administration), followed by delayed drug 
treatment (intraperitoneal or oral) and/or antivenom (intraperitoneal or intravenous). (A) Survival 
of mice receiving E. ocellatus venom (intraperitoneally) followed by 168 µl of the E. ocellatus 
monospecific antivenom EchiTAbG either intraperitoneally 15 min later or intravenously 1 h 
later. Corresponding TAT concentrations for the envenomed animals are depicted on the right. 
Note: For the venom + AV intraperitoneally (15 min) dataset, the mouse that succumbed early to 
the effects of the venom could not be sampled for TAT, therefore the data displayed only reflect 
the animals that survived until the end of the experiment. (B) Survival of mice receiving E. 
ocellatus venom (intraperitoneally) followed by DMPS 15 min later (120 µg, intraperitoneally) 
and antivenom 1 h after venom administration (168 µl, intravenously). Right panel shows 
corresponding TAT concentrations. (C) Survival of mice receiving E. ocellatus venom 
(intraperitoneally), followed immediately by: (i) oral DMPS (600 µg, ~1 min after venom 
injection), (ii) oral DMPS (600 µg, ~1 min after venom injection) and EchiTAbG antivenom 
(168 µl, intravenously, 1 h later), and (iii) EchiTAbG antivenom (168 µl, intravenously, 1 h 
later). Right panel shows corresponding TAT concentrations. For all survival experiments, drug- 
or antivenom-only controls are presented as black dotted lines at the top of each graph (none 
exhibited toxicity at the given doses), and the end of the experiment was at 24 h. For 
quantification of TAT, where the time of death was the same within experimental groups (early 
deaths or complete survival), TAT concentrations were quantified for n=3, and where times of 
death varied, n=5. The data are displayed as means of the duplicate technical repeats plus SDs. 
 
Fig. 8. DMPS effectively neutralizes local hemorrhage caused by E. ocellatus venom. 
(A) The resulting murine hemorrhagic lesions observed 2 h after the intradermal injection of 
(from left to right): (i) 10 µg E. ocellatus venom, (ii) 10 µg E. ocellatus venom preincubated (30 
min at 37 C) with 13.3 µg DMPS, (iii) 13.3 µg DMPS, and (iv) PBS control. For all 
experimental groups, n=3. Black lines represent scale bars equivalent to 2 mm. (B) 
Quantification of hemorrhagic lesion sizes expressed as the hemorrhagic area (mm2) observed 2 
h after injection. The data are expressed as the mean of triplicate measurements ± SEM. A two-
tailed unpaired t-test was used to compare the lesion sizes in the venom-only vs. venom+ DMPS 




Materials and Methods 
Venoms 
Venoms were sourced from either wild-caught specimens maintained in, or historical venom 
samples stored in, the Herpetarium of the Liverpool School of Tropical Medicine (LSTM). The 
venom pools selected encompassed saw-scaled vipers from diverse geographical localities and 
were from: E. ocellatus (Nigeria), E. carinatus sochureki (India, referred to throughout as E. 
carinatus), E. carinatus sochureki (U.A.E, also referred to as E. carinatus), E. pyramidum 
leakeyi (Kenya, referred to as E. pyramidum), E. leucogaster (Mali), and E. coloratus (Egypt). 
Note that the Indian E. carinatus venom was collected from a single specimen that was 
inadvertently imported to the UK via a boat shipment of stone, and then rehoused at LSTM on 
the request of the UK Royal Society for the Prevention of Cruelty to Animals. Crude venoms 
were lyophilized and stored at 4 °C to ensure long-term stability. Before use, venoms were 
resuspended to 10 mg/ml in PBS (pH 7.4) and then further diluted to 1 mg/ml stock solutions 
(with PBS) for the described experiments. 
 
Metal chelators 
Dimercaprol (2,3-dimercapto-1-propanol ≥98 % iodometric, Cat no:64046-10 ml), DMSA 
(meso-2,3-dimercaptosuccinic acid ≥98 % by HPLC, Cat no: D7881-1G), and EDTA (E6758) 
were purchased from Sigma-Aldrich. DMPS (2,3-dimercapto-1-propanesulfonic acid sodium salt 
monohydrate, 95%, Cat no: H56578) was sourced from Alfa Aesar. Stocks (tenfold dilutions 
from 2 mM to 2 µM) were made using deionized water, with the exception of the 2 mM DMSA 
stock, which was made using 100% ethanol, because it is insoluble in water at this concentration. 
DMPS was resuspended in PBS.  
 
Venomics 
The proteome of E. leucogaster (Mali) venom was inferred by comparing the reverse-phase 
HPLC traces and SDS-PAGE analyses of the chromatographic fractions with those of the 
previously reported (11) venom proteomes of E. ocellatus (Nigeria), E. carinatus (U.A.E. and 
India), E. pyramidum (Kenya), and E. coloratus (Egypt), and the partially characterized venom 
proteome of E. leucogaster (Mali) (59). The relative abundances (expressed as percentage of the 
total venom proteins) of the different protein families were calculated from the relation of the 
sum of the areas of the reverse-phase chromatographic peaks (containing proteins from the same 
toxin family) to the total area of venom protein peaks in the reverse-phase chromatogram. The 
relative contributions of different proteins eluting in the same chromatographic fraction was 
estimated by densitometry of Coomassie brilliant blue-stained SDS-PAGE gels, as previously 
outlined (60).    
 
SVMP assay 
The SVMP activity of the various venoms, in the presence or absence of inhibitors, was 
measured using a quenched fluorogenic substrate (ES010, R&D Biosystems). Briefly, 10 µl of 
the substrate (supplied as a 6.2 mM stock) was used per 5 ml reaction buffer (150 mM NaCl, 50 
mM Tris-Cl pH 7.5). Reactions consisted of 10 µl of venom ± inhibitors in PBS and 90 µl of 
substrate. Venoms were used at 1 µg/reaction, and the final concentrations of the various 
inhibitors ranged from 150 µM to 150 nM (tenfold dilutions). The venom and inhibitors were 
preincubated for 30 min at 37 ºC and pipetted in triplicate onto 384-well plates (Greiner). A 
Labsystems Multidrop Reagent dispenser was used to dispense the substrate. The plate was run 
on an Omega FLUOstar (BMG Labtech) instrument at an excitation wavelength of 320 nm and 
emission wavelength of 405 nm at 25 ºC for 1 h. The areas under the curve (AUCs) in the 0-40 
min interval were calculated for each sample; this time point was chosen as the time where all 
fluorescence curves had reached a plateau (maximum fluorescence). For comparing venom-only 
samples, the averages of at least three independent experimental runs for each condition, 
expressed as AUCs (n ≥ 3), were plotted at each inhibitor concentration with standard error of 
the mean (SEM). To determine inhibitor efficacy, the AUCs for each of the samples that 
consisted of venom + inhibitors were transformed and expressed as percentages of the venom-
only sample (where the venom was 100%). The negative control (PBS only) was also expressed 
relative to the venom, and the variation in background was presented as an interval (dotted black 
lines) delineated by the lowest and highest values in the PBS-only samples across concentrations 
and inhibitors for a specific venom. 
 
Plasma assay 
To assess the pro- or anti-coagulant activity of our venoms, we used a previously published 
method (32). Briefly, 100 ng of each venom was incubated at 37 ºC for 30 min in the presence or 
absence of inhibitors, whose concentrations ranged from 150 µM to 150 nM (tenfold dilutions). 
The final reaction consisted of 10 µl venom ± inhibitors in PBS, 20 µl 20 mM CaCl2, and 20 µl 
citrated bovine plasma (VWR). The samples were pipetted in triplicate onto 384-well plates, and 
the absorbance was monitored at 595 nm for 2 h at 25 ºC on an Omega FLUOstar instrument 
(kinetic cycle ~68 s). We calculated the maximum clotting velocity of each of the curves as per 
clot waveform analysis (61), by calculating the maximum of the first derivative. The averages of 
at least three independent experimental runs for each condition were plotted at each inhibitor 
concentration with SEMs.  
 
Prothrombin degradation 
To assess the ability of the venoms to degrade prothrombin, we incubated 5 µg of venom with 5 
µg of prothrombin (Haematological Technologies, Inc.) in the presence or absence of inhibitors 
(at 150 and 500 µM) in a final volume of 15 µl. Venoms and inhibitors were preincubated at 37 
ºC for 30 min, after which prothrombin was added, followed by another 10 min incubation at 37 
ºC. The reaction was stopped by adding an equivalent volume of 2X PAGE-loading dye 
containing β-mercaptoethanol, after which the samples were heated at 100 ºC for 5 min. The 
entire sample volume (30 µl) was loaded and run on 4-20% 12-well Novex precast gels (Thermo 
Fisher) and visualized with Coomassie Brilliant Blue. 
 
In vivo studies 




For all experimental animals, blood samples were collected via cardiac puncture immediately 
after euthanasia. Plasma was separated by centrifugation at 400 x g for 10 min and stored at −80 
ºC. We assessed the concentrations of TAT complexes using a mouse ELISA Kit (Abcam, 
ab137994), following the manufacturer’s protocol. Mouse plasma samples were diluted 1:100 or 
1:150 to fit within the linear range of the assay and measurements were performed in duplicate. 
All available plasma samples (some were unobtainable via cardiac puncture due to extensive 
internal hemorrhage) were assessed if the time of death within the group varied, whereas three 
samples were randomly chosen if the time of death was the same (either very rapid death within 
2 minutes, or survival until the end of the experiment ~360 min or 24 h). The resulting data were 
plotted as the medians of duplicate measurements for each animal and are presented with 
standard deviations (SDs). 
 
Assessments of RBC morphology via microscopy 
For the preclinical experiments involving the preincubation and delayed oral administration of 
DMPS, immediately after blood samples were collected via cardiac puncture, thin blood films 
were prepared and left to air dry overnight. They were then fixed for 60 seconds in methyl 
alcohol and stained with 10% Giemsa. The slides were allowed to dry overnight, and a coverslip 
was mounted using DPX mounting medium. After this, blood films were examined using a 100x 
objective under oil immersion using a Leica ICC50W microscope. The morphology of red blood 
cells in the monolayer, including size, shape, and color was recorded. 
 
Echis ocellatus venom fractionation 
Proteins from E. ocellatus venom (50 mg in 5 ml of PBS) were separated using gel filtration 
chromatography on a Superdex 200 matrix packed in a 2.6 x 100 cm (500 ml) column. The 
column was run at 2 ml/min in PBS, and elution was monitored at 280 nm. Fractions of 6 ml 
were collected and the protein content analyzed by SDS-PAGE under reducing conditions using 
4-20% gradient gels as above [see “Prothrombin degradation”]. Key fractions were assayed for 
serine protease and PLA2 activity, as described below. 
 
Serine protease assay 
To determine the serine protease activity of the various E. ocellatus venom fractions, we used a 
chromogenic kinetic assay and the specific substrate S-2288 (Cambridge Biosciences). Samples 
(5 µl of each fraction) were plated onto 384-well plates, and then overlaid with buffer (100 mM 
Tris-Cl, 100 mM NaCl, pH 8.5) and 6 mM of S-2288. Changes in absorbance were measured at 
405 nm for ~30 min. Negative control (PBS) readings were subtracted from each reading and the 
rate of substrate consumption calculated by measuring the slope between 0 and 5 min. To assess 
inhibition by DMPS, samples that displayed activity were preincubated with DMPS at a final 
concentration of 150 µM for 30 min at 37 ºC and assayed as described above. The means of 
duplicate or triplicate measurements with SDs were plotted.  
 
PLA2 assay 
To assess PLA2 activity, we used the EnzChek Phospholipase A2 Assay Kit (#E10217, Fisher 
Scientific), following the manufacturer’s instructions. Briefly, 5 μl of the various venom 
fractions were assayed and compared with the bee venom standard, alongside a negative control 
containing no venom. For testing DMPS efficacy in the fractions which displayed PLA2 activity, 
DMPS at a final concentration of 150 µM was preincubated with the fractions for 30 min at 37 
ºC and a drug-only control was also measured. A standard activity curve was generated using 5, 
4, 3, 2, 1, and 0 U/ml of bee PLA2 enzyme present in the kit. Fifty microliter samples were 
mixed with 50 μl of substrate mix, and the reaction was incubated in the dark for 10 min. End-
point fluorescence was then measured on a FLUOstar Omega Instrument at an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm. The negative control was 
subtracted from the raw values for each sample, and PLA2 activity was calculated (U/ml) in each 












Fig. S2. The snake venom metalloproteinase and plasma clotting activity of saw-scaled 
viper venoms. 
(A) The SVMP activity (expressed as area under the curve at 40 min) of six Echis venoms 
determined using an in vitro kinetic fluorescent assay. The average and SEM of n=6 repeats 
consisting of at least two technical replicates is displayed. (B) The maximum clotting velocity 
(calculated as the maximum of the first derivative of each clotting curve) of six Echis venoms 
determined using an in vitro kinetic absorbance assay. The average and SEM of n=6 repeats 





Fig. S3. Metal chelators inhibit the procoagulant activity of saw-scaled viper venoms in the 
absence of calcium.  
The neutralizing capability of four metal chelators against the Ca2+-independent procoagulant 
activity of five Echis venoms. Data are presented for four drug concentrations, from 150 µM to 
150 nM (highest to lowest dose), expressed as the maximum clotting velocity (dotted red lines 
indicate the maximal clotting velocity of the venom). The negative control is presented as an 
interval (dotted black lines) and represents normal plasma clotting (expressed as plasma-only 
maximal clotting velocity). The middle dotted lines represent the average maximal clotting 
velocity of the venom (red) and plasma (black), with the interval on either side indicating the 
average ± SEM. Note that these dotted lines may appear as a single line if the interval is very 
narrow and lines overlap. Inhibitors are color-coded (dimercaprol, red; DMPS, blue; EDTA, dark 
blue). The data represent triplicate independent repeats with SEMs, where each repeat represents 
the average of n≥2 technical replicates. Bottom right: maximum clotting velocity for each 
venom. Note that the procoagulant activity of E. coloratus venom is Ca2+-dependent, and no 





Fig. S4. Degradation of prothrombin by saw-scaled viper venoms and inhibition of this 
activity by metal chelators. 
The neutralizing capability of four metal chelators against the prothrombin activating activity of 
six Echis venoms determined by SDS-PAGE gel electrophoresis. Each chelator was tested at two 
different concentrations (150 µM and 500 µM) and was preincubated with venom (30 min at 37 
°C), followed by a 10 min incubation at 37 °C with prothrombin. Controls include prothrombin 
only (P), venom only (V), venom + prothrombin (V+P, positive control for degradation). M 
represents the protein marker. The red arrow indicates prothrombin (~72 kDa). Meizothrombin, 










Fig. S5. Correlations between in vivo survival and TAT concentrations. 
Plots of experimental animal survival times versus TAT concentrations. The plots represent data 
from animals that received intravenous treatment after a 30 min preincubation between the 
venom and drug (left), and those that received the intraperitoneal treatment with drug 15 min 
after intraperitoneal venom delivery (right). Data points at 360 min (left) and 1440 min (right) 
represent animals that survived to the end of the experiments, and all other data points represent 





Fig. S6. Red blood cell (RBC) morphology of envenomed and treatment groups from the 
coincubation model of envenoming. 
Thin blood films of each group of mice were generated, stained with 10% Giemsa, and analyzed 
using a Leica ICC50W microscope with 100 x objective. Echis spp. venom: approximately 90% 
of RBCs are echinocytes (RBCs with numerous projections of the cell membrane, which are 
evenly spaced around the circumference). These are mostly microcytic (smaller than the mean 
size of 6-8 µm expected in normal, healthy mice). In E. ocellatus envenoming, there are also 
codocytes present (RBCs which have a “lump” of hemoglobinized cytoplasm within the area of 
normal central pallor). Venom + DMPS: more than 90% of cells appear normal, although there 
are a few schistocytes (RBC fragments) present. There are also infrequent dacrocytes (tear drop 
shape), which is normal. In E. carinatus and E. pyramidum envenoming, there appears to be a 
moderate presentation of ghost cells (lysed RBCs). Non-envenomed mice, including normal: 
RBCs are mostly normal, with a mean size of 6-8 µm, a biconcave shape, and purple cytoplasm 
with a small central pallor (approximately one third of the cell diameter) and DMPS: RBCs 
appear normal in shape and size, although a large central pallor is present (greater than two thirds 
of the cell), indicating possible hypochromasia (RBCs have less hemoglobin than normal). Scale 




Fig. S7. RBC morphology after early oral administration of DMPS and delayed antivenom 
treatment. 
Thin blood films of each group of mice were generated, stained with 10% Giemsa, and analyzed 
using a Leica ICC50W microscope with 100 x objective. Non-envenomed mice: RBCs are 
mostly normal, with a mean size of 6-8 µm, a biconcave shape, and purple cytoplasm with a 
small central pallor (approximately one third of the cell diameter). Venom (E. ocellatus) (ip): 
approximately 90% of RBCs are echinocytes (RBCs with numerous projections of the cell 
membrane, which are evenly spaced around the circumference). Venom (ip) + DMPS (oral): 
there is a potential ‘rescue’ of RBCs. Less than 10% of RBCs are echinocytes, although still 
present, and there are low numbers of schistocytes (RBC fragments) present, indicating 
mechanical trauma. DMPS (oral): RBCs appear normal in shape and size, although a large 
central pallor is present (greater than two thirds of the cell), indicating possible hypochromasia 
(RBCs have less hemoglobin than normal). Venom (ip) + AV (1 h): echinocytes present in very 
low numbers (less than 5% of cells), and some ghost cells are present (lysed RBCs). Venom (ip) 
+ DMPS (oral) + AV (1 h): Very few echinocytes are present, although the cells appear 
hypochromic and there is anisocytosis (variation in cell size) present. Ghost cells and 
schistocytes are also present in low numbers. Scale bars = 10 µm.  
 
 
Fig. S8. DMPS does not inhibit the serine protease or PLA2 activities of E. ocellatus venom. 
(A) Arbitrarily numbered sequential fractions of E. ocellatus venom (10 µl) separated on 
Superdex 200 and analyzed on 4-20% SDS-PAGE gels under reducing conditions. (B) Serine 
protease activity of the resulting E. ocellatus venom fractions (top), and the effect of DMPS on 
the serine protease activity in those fractions (bottom, n=2 repeats with SDs), showing no 
inhibitory activity. (C) PLA2 activity of the resulting E. ocellatus venom fractions (top), and the 
effect of DMPS on the PLA2 activity in those fractions (bottom, n=2 repeats with SDs), showing 
no inhibitory activity. PBS, the negative control, readings have been subtracted from all 
displayed data. 
 
 
 
